Loading the recordsβ¦
Loading the recordsβ¦
BILL ANALYSIS
HR7902 (To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.
neutral
Market Sentiment
5/10
Impact Score
1
Sectors Impacted
HR 7902 is early-stage legislation with very low near-term passage probability (6 cosponsors, no committee action)
Revenue exposure to $PFE and $TEVA is immaterial β less than 0.1% of annual revenue for either company
$TEVA's 15% weekly gain and $PFE's 5% monthly decline are driven by company-specific catalysts, not abortion legislation
No federal spending is authorized β funding_amount is $0
This bill has negligible market implications. $PFE at $26.71 (near 52-week low of $21.97) faces headwinds from LoE on Xeljanz, Ibrance, and Eliquis patent cliffs β not from a low-revenue product like mifepristone. $TEVA at $35.26 (near 52-week high of $37.35) is rallying on positive pipeline news and AJOVY/COPAXONE generic defense. Traders should not factor HR 7902 into positions on either stock. The only scenario that would change the market calculus is a surprise markup or hearing scheduling that signals bill progression β currently no evidence of that.
| Metric | Value |
|---|---|
| Bill Number | HR7902 |
| Market Sentiment | neutral |
| Event Date | |
| Affected Sectors | Healthcare |
| Source | View on Congress.gov β |
HR 7902 (Safeguarding Women from Chemical Abortion Act) would withdraw FDA approval for mifepristone for pregnancy termination and create a federal tort for harm from chemical abortion drugs. The bill was introduced March 12, 2026, referred to two committees, and is in early legislative stages with only 6 cosponsors. Revenue exposure for $PFE and $TEVA is immaterial to their overall financials β less than 0.1% of revenue for each. The bill has effectively no near-term market impact.
Free β no credit card
HillSignal scores every bill, federal contract, and insider filing for market impact and emails you the high-conviction ones. Free, no credit card.
Weekly digest β the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan Β· No credit card Β· Unsubscribe in one click
Want the live terminal too? Create a free account β
Β© 2026 HillSignal. All rights reserved.
Not financial advice. For informational purposes only.